KIF5B Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population offering a loss-of-function model for the KIF5B gene in a human lung adenocarcinoma background. This polyclonal format avoids clonal bias by providing a heterogeneous pool of gene-disrupted A-549 cells, enabling robust assessment of KIF5B-dependent phenotypes.
The parental A-549 cell line, derived from a 58-year-old Caucasian male with lung carcinoma, is an epithelial model exhibiting type II alveolar cell features and is widely used to study respiratory epithelial biology and NSCLC signaling. Its adherent growth and well-documented EGFR expression make it a relevant host for knockout studies targeting intracellular transport pathways.
KIF5B encodes the kinesin-1 heavy chain, a plus-end-directed microtubule motor responsible for anterograde transport of vesicles, mitochondria, lysosomes, and signaling endosomes. Motor activity is regulated by MAPK/ERK phosphorylation and Ca2+/calmodulin, and cargo selectivity is conferred through adaptors: TRAK1/2 (mitochondria), JIP3 (lysosomes), and HAP1 (autophagosomes). KIF5B forms heterotetramers with kinesin light chains KLC1/2 and interacts with the dynactin-dynein complex for bidirectional motility. Consequently, KIF5B coordinates the intracellular distribution of EGFR-containing endosomes and organelles, thereby influencing receptor signaling, metabolic positioning, and cytoskeletal organization.
In A-549 cells, KIF5B disruption directly impairs the microtubule-dependent trafficking of EGFR, potentially delaying receptor degradation and sustaining proliferative and survival signals such as MAPK/ERK. This model captures the pathological relevance of KIF5B in lung adenocarcinoma, where the motor is also observed as a fusion partner in oncogenic rearrangements (e.g., KIF5B-RET). Furthermore, the knockout context can be extended to study conserved motor protein pathology relevant to neurodegenerative diseases like hereditary spastic paraplegia and Charcot-Marie-Tooth type 2, which are caused by KIF5B mutations.
Key applications include dissecting kinesin-1 roles in EGFR trafficking and lung cancer cell migration, evaluating drug resistance to motor inhibitors, and probing the mechanistic basis of organelle mislocalization. Compatible assays range from biochemical methods (Western blot, co-immunoprecipitation) to imaging-based techniques (immunofluorescence, live-cell tracking) and functional assays (proliferation, EGFR internalization, transwell migration). For further inquiries, please contact Ascent Research.
